Endava Shares Plunge as Morningstar Slashes Valuation

Morningstar has delivered a stunning blow to Endava, cutting its fair value estimate for the IT services firm by precisely half in one of the most severe valuation downgrades witnessed in US markets. The research firm now values the company’s shares at $13.60, a dramatic reduction from its previous $27.00 assessment, placing Endava among the market’s worst-performing equities.

Operational Setbacks Trigger Drastic Reassessment

This substantial valuation cut stems directly from disappointing business performance. Market analysts point to several critical factors behind the downward revision:

• First fiscal quarter results that failed to meet expectations
• Management’s weakened outlook for the second quarter
• A downwardly revised annual forecast from company leadership
• Reduced growth rates and EBIT margins incorporated into financial models

The 27% single-day plunge in Endava’s share price on November 11 reflects these operational challenges, though Morningstar maintains an intriguing stance despite the bleak picture.

Contrarian Opportunity Emerges from Market Pessimism

In a surprising counterpoint to its valuation cut, Morningstar continues to assign Endava a 5-star rating. This suggests that despite the company’s operational headwinds, the market may have overcorrected in its negative response. The rating indicates that current share prices potentially undervalue the company’s underlying strengths, presenting a potential opportunity for investors willing to navigate the current turbulence.

Should investors sell immediately? Or is it worth buying Endava?

The situation creates a complex investment proposition: does the mathematical undervaluation signaled by the 5-star rating outweigh the concerning operational realities that prompted the valuation cut?

Ranking Among Market Laggards

Endava finds itself in concerning company, joining Intellia Therapeutics (down 55%) and Optimum Communications (down 50%) as the biggest losers in Morningstar’s latest valuation review. This performance stands in stark contrast to the broader market, which saw average valuation increases of 2.5% during the same period.

For current and prospective shareholders, the central dilemma remains whether to trust the quantitative signal of potential undervaluation or heed the qualitative warning of operational deterioration. The resolution of this tension between price and performance will ultimately determine Endava’s trajectory in coming quarters.